Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate‐specific antigen velocity

Background:  Current diagnostic tools are inadequate for reliable prediction of prostate cancer (PCa) aggressiveness in patients with localised disease. This results in many patients being exposed to potentially unnecessary invasive treatment and its associated morbidities. In order to develop appropriate treatment strategies, it is essential to understand the differences between patients who will develop aggressive disease and those who will not.

[1]  Chiu-Hsieh Hsu,et al.  Oral Selenium Supplementation Has No Effect on Prostate-Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer , 2010, Cancer Prevention Research.

[2]  P. Carroll,et al.  Active surveillance for early-stage prostate cancer: defining the triggers for intervention. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Chiu-Hsieh Hsu,et al.  Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity , 2010, The Prostate.

[4]  B. Delahunt,et al.  Prostate cancer: the new evidence base for diagnosis and treatment , 2007, Pathology.

[5]  E. Platz,et al.  Inflammation in the etiology of prostate cancer: an epidemiologic perspective. , 2007, Urologic oncology.

[6]  M. Thun,et al.  A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. , 2007, Journal of the National Cancer Institute.

[7]  Hans Lilja,et al.  Circulating biomarkers for prostate cancer , 2007, World Journal of Urology.

[8]  C. Bangma,et al.  Overdiagnosis and overtreatment of early detected prostate cancer , 2007, World Journal of Urology.

[9]  L. Ferrucci,et al.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.

[10]  Pankaj K Choudhary,et al.  Critical analysis of prostate‐specific antigen doubling time calculation methodology , 2006, Cancer.

[11]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[12]  Ruth Etzioni,et al.  Associations of demographic and lifestyle characteristics with prostate‐specific antigen (PSA) concentration and rate of PSA increase , 2006, Cancer.

[13]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[14]  E. Metter,et al.  Nonsteroidal Anti-inflammatory Drugs and Risk of Prostate Cancer in the Baltimore Longitudinal Study of Aging , 2005, Cancer Epidemiology Biomarkers & Prevention.

[15]  D. Bostwick,et al.  Human prostate cancer risk factors , 2004, Cancer.

[16]  Jaime Pujadas Oláno,et al.  Natural history of early localized prostate cancer. , 2004, JAMA.

[17]  A. Aprikian,et al.  Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis , 2004, British Journal of Cancer.

[18]  E. Rimm,et al.  Smoking and risk of total and fatal prostate cancer in United States health professionals. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[20]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Prando.  Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program , 2010 .

[22]  G. Chodak,et al.  Watchful waiting for prostate cancer: a review article , 2006, Prostate Cancer and Prostatic Diseases.

[23]  A. D'Amico,et al.  Prostate‐specific antigen velocity and survival for patients with hormone‐refractory metastatic prostate carcinoma , 2006, Cancer.

[24]  L. Klotz.  Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer. , 2005, European urology.

[25]  K. Do,et al.  Smoking and prostate cancer. , 2001, Epidemiologic reviews.

[26]  U. G. Dailey.  Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.